These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25846027)

  • 1. Re: Editorial Comment on Clinical Performance of Serum Isoform (-2)proPSA (p2PSA) and its Derivatives, Namely %p2PSA and PHI (Prostate Health Index) in Men Younger than 60 Years of Age: Results from a Multicentric European Study: S. S. Taneja J Urol 2014;192:421.
    Fossati N; Lazzeri M; Larcher A
    J Urol; 2015 Jul; 194(1):265; author reply 265-6. PubMed ID: 25846027
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Clinical performance of serum isoform (-2)proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study.
    Taneja SS
    J Urol; 2014 Aug; 192(2):421. PubMed ID: 25034991
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
    Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
    BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
    Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
    Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.
    Lazzeri M; Briganti A; Scattoni V; Lughezzani G; Larcher A; Gadda GM; Lista G; Cestari A; Buffi N; Bini V; Freschi M; Rigatti P; Montorsi F; Guazzoni G
    J Urol; 2012 Oct; 188(4):1137-43. PubMed ID: 22901578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
    Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
    Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum p2PSA derivative indexes in prostate cancer: an update].
    Liu Y; Xu Y
    Zhonghua Nan Ke Xue; 2015 Jan; 21(1):74-7. PubMed ID: 25707145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.
    Abrate A; Lazzeri M; Lughezzani G; Buffi N; Bini V; Haese A; de la Taille A; McNicholas T; Redorta JP; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Freschi M; Guazzoni G
    BJU Int; 2015 Apr; 115(4):537-45. PubMed ID: 25130593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.
    Wang W; Wang M; Wang L; Adams TS; Tian Y; Xu J
    Sci Rep; 2014 May; 4():5012. PubMed ID: 24852453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
    Abrate A; Simonato A
    Scand J Urol; 2017 Aug; 51(4):258-259. PubMed ID: 28398109
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Huang D; Ruan X; Wu Y; Lin X; Huang J; Ye D; Gao Y; Ding Q; Xu D; Na R
    Prostate; 2021 Sep; 81(13):971-982. PubMed ID: 34254325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
    Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
    Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.
    Hirama H; Sugimoto M; Ito K; Shiraishi T; Kakehi Y
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):257-63. PubMed ID: 24352745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.